English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [1386]
News [2583]
Articles [24]
Editorials [0]
Conferences [149]
elearning [15]
New targeted radionuclide alpha therapy improves prostate cancer outcomes
New targeted radionuclide alpha therapy improves prostate cancer outcomes
EHA 2022: Transforming transfusion-dependent β-thalassemia and sickle cell disease with a single CRISPR/Cas9 gene-edited therapy
EHA 2022: Transforming transfusion-dependent β-thalassemia and sickle cell disease with a single CRISPR/Cas9 gene...
EHA 2022: Dysregulation of RNA binding proteins drive hematopoietic stem cell exhaustion and bone marrow failure
EHA 2022: Dysregulation of RNA binding proteins drive hematopoietic stem cell exhaustion and bone marrow failure
Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy
Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy
Bridge therapy may benefit some children with high-risk neuroblastoma
Bridge therapy may benefit some children with high-risk neuroblastoma
ASCO 2022: Autologous stem cell transplant showed improved progression-free survival in newly diagnosed multiple myeloma patients
ASCO 2022: Autologous stem cell transplant showed improved progression-free survival in newly diagnosed multiple...
ASCO 2022: Combination regimen improves overall survival in a type of newly diagnosed metastatic colorectal cancer
ASCO 2022: Combination regimen improves overall survival in a type of newly diagnosed metastatic colorectal cancer
ASCO 2022: Lung cancer therapy could help patients live longer
ASCO 2022: Lung cancer therapy could help patients live longer
ASCO 2022: Drug combination shows promise against cancer’s ‘death star’ protein
ASCO 2022: Drug combination shows promise against cancer’s ‘death star’ protein
ASCO 2022: Novel agent increases PFS for patients with the most common type of advanced breast cancer
ASCO 2022: Novel agent increases PFS for patients with the most common type of advanced breast cancer
<1...979899100101...259>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top